Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Not Yet Opened 07-08 16:00:00 EDT

6.13

+0.23

+3.90%

盘后6.15

+0.02+0.33%

19:56 EDT

High6.21	Low5.66	Vol1.05M
Open5.73	D1 Closing5.90	Amplitude9.32%
Mkt Cap191.81M	Tradable Cap113.29M	Total Shares31.29M
T/O6.30M	T/O Rate5.70%	Tradable Shares18.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":6.13,"timestamp":1783540800000,"preClose":5.9,"halted":0,"volume":1053651,"hourTrading":{"tag":"盘后","latestPrice":6.15,"preClose":6.13,"latestTime":"19:56 EDT","volume":22540,"amount":138196.4788,"timestamp":1783554970481,"change":0.02,"changeRate":0.003263,"amplitude":0.006525},"delay":0,"changeRate":0.03898305084745755,"floatShares":18481200,"shares":31289969,"eps":-3.661292,"marketStatus":"Not Yet Opened","change":0.23,"latestTime":"07-08 16:00:00 EDT","open":5.73,"high":6.21,"low":5.66,"amount":6299628.2354466,"amplitude":0.09322,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.661292,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783584000000},"marketStatusCode":0,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":5.9,"preHourTrading":{"tag":"盘前","latestPrice":5.8936,"preClose":5.9,"latestTime":"09:02 EDT","volume":451,"amount":2632.4637284,"timestamp":1783515773423,"change":-0.0064,"changeRate":-0.001085,"amplitude":0.1},"postHourTrading":{"tag":"盘后","latestPrice":6.15,"preClose":6.13,"latestTime":"19:56 EDT","volume":22540,"amount":138196.4788,"timestamp":1783554970481,"change":0.02,"changeRate":0.003263,"amplitude":0.006525},"volumeRatio":0.978735,"impliedVol":1.558,"impliedVolPercentile":0.94},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2650467109","title":"Alterity Therapeutics Receives AU$4 Million Tax Refund From Australian Government","url":"https://stock-news.laohu8.com/highlight/detail?id=2650467109","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650467109?lang=en_us&edition=fundamental","pubTime":"2026-07-09 14:14","pubTimestamp":1783577646,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  received a research and development tax refund from the Australian government of about AU$4 million for the fiscal year 2025, according to a Thursday filing with the Australian bourse.The tax incentive provides the company with \"important funding\" to support the development of its clinical programs, Alterity said.The company's shares gained 2% on market close.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["E200.AU","BBOZ.AU","BEAR.AU","IOZ.AU","SLF.AU","XKO.AU","BK4139","LENZ","ZYAU.AU","ATH.AU","BK7067","IIGF.AU","QFN.AU","VAS.AU","OZR.AU","EIGA.AU","GIVE.AU","IMLC.AU","BK4007","GEAR.AU","QRE.AU","VAP.AU","XJO.AU","BK4539","DACE.AU","XAO.AU","OZF.AU","STW.AU","IISV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650108509","title":"Insider Move: Larimar Therapeutics Director Makes Bold New Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2650108509","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650108509?lang=en_us&edition=fundamental","pubTime":"2026-07-09 10:01","pubTimestamp":1783562473,"startTime":"0","endTime":"0","summary":"New insider activity at Larimar Therapeutics ( ($LRMR) ) has taken place on July 8, 2026. Director Thomas Edward Hamilton has signaled confidence i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-move-larimar-therapeutics-director-makes-bold-new-stock-purchase-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-move-larimar-therapeutics-director-makes-bold-new-stock-purchase-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650191086","title":"Alterity Therapeutics Seeks ASX Quotation for New Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650191086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650191086?lang=en_us&edition=fundamental","pubTime":"2026-07-09 09:52","pubTimestamp":1783561933,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($AU:ATH) ) has issued an announcement. Alterity Therapeutics has applied to the Australian Securities Exchange for quotati...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-seeks-asx-quotation-for-new-ordinary-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-seeks-asx-quotation-for-new-ordinary-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650304914","title":"Enlivex Therapeutics trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2650304914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650304914?lang=en_us&edition=fundamental","pubTime":"2026-07-09 07:50","pubTimestamp":1783554617,"startTime":"0","endTime":"0","summary":"19:50 EDT Enlivex Therapeutics (ENLV) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving bre...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enlivex-therapeutics-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enlivex-therapeutics-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","ENLV","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650748915","title":"Larimar Therapeutics director buys $167K in common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2650748915","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650748915?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:10","pubTimestamp":1783541411,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Larimar Therapeutics (LRMR) disclosed that its director, Thomas Hamilton, bought 50,000 shares of common stock on July 6th ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-director-buys-167k-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-director-buys-167k-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650915633","title":"Tvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2650915633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650915633?lang=en_us&edition=fundamental","pubTime":"2026-07-09 03:40","pubTimestamp":1783539646,"startTime":"0","endTime":"0","summary":"As previously reported, Piper Sandler analyst Yasmeen Rahimi upgraded Tvardi Therapeutics (TVRD) to Overweight from Neutral with a price target of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-upgraded-to-overweight-at-piper-after-phase-1-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-upgraded-to-overweight-at-piper-after-phase-1-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650913987","title":"Tvardi Therapeutics Shares Rise After Raymond James Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2650913987","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650913987?lang=en_us&edition=fundamental","pubTime":"2026-07-09 02:55","pubTimestamp":1783536912,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics (TVRD) shares rose more than 52% in Wednesday trading after Raymond James upgraded the stock to outperform from market perform.Trading volume stood at more than 31.6 million shares, compared with a daily average of 1.3 million.Price: 4.69, Change: +1.59, Percent Change: +51.29","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650005990","title":"Beam Therapeutics Price Target Maintained with a $47.00/share by B of a Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2650005990","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650005990?lang=en_us&edition=fundamental","pubTime":"2026-07-09 01:34","pubTimestamp":1783532040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BEAM/analyst-ratings(END) Dow Jones NewswiresJuly 08, 2026 13:34 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650997099","title":"Independent Pharmacies Accuse Prime Therapeutics of Price-Fixing Scheme With Express Scripts","url":"https://stock-news.laohu8.com/highlight/detail?id=2650997099","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650997099?lang=en_us&edition=fundamental","pubTime":"2026-07-09 00:27","pubTimestamp":1783528020,"startTime":"0","endTime":"0","summary":"According to the complaint, TRUST LLC, a Virginia limited liability company formed in 2023 by the National Community Pharmacists Association, represents nearly 5,000 independent pharmacies that assigned their claims to the organization.The lawsuit states that Prime introduced a mandatory arbitration amendment to its Pharmacy Participation Agreements, effective December 1, 2024, requiring disputes to be resolved before JAMS.Bloomberg Law published a copy of the lawsuit online last week.TRUST LLC says it complied with that requirement by filing a demand for arbitration in October 2025 and subsequently provided Prime with assignment documentation for participating pharmacies.However, the complaint alleges Prime later argued that many pharmacies were not subject to the JAMS provision and instead should proceed before the American Arbitration Association , without identifying which pharmacies were affected.According to the complaint, the plaintiffs claim the agreement allowed Prime to match","market":"hk","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=630,format=auto,quality=85/files/images/story/2026/07/08/Pharmacy--Pills-And-Box-With-Healthcare-.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=630,format=auto,quality=85/files/images/story/2026/07/08/Pharmacy--Pills-And-Box-With-Healthcare-.jpg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/07/60339005/independent-pharmacies-accuse-prime-therapeutics-of-price-fixing-scheme-with-express-scripts","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/07/60339005/independent-pharmacies-accuse-prime-therapeutics-of-price-fixing-scheme-with-express-scripts","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4007","ESRX","BK4139","AAA","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995089","title":"Allotera Therapeutics closes $35M financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649995089?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:15","pubTimestamp":1783516512,"startTime":"0","endTime":"0","summary":"Allotera Therapeutics announced the closing of a $35M financing round comprising equity and venture debt. The company also introduced its new name,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/allotera-therapeutics-closes-35m-financing-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/allotera-therapeutics-closes-35m-financing-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649569995","title":"JPMorgan Initiates BridgeBio Oncology Therapeutics at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2649569995","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649569995?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:14","pubTimestamp":1783512841,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics, Inc. (BBOT) has an average rating of buy and mean price target of $25.30, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JPM","LENZ","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649996156","title":"Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2649996156","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649996156?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:00","pubTimestamp":1783512000,"startTime":"0","endTime":"0","summary":"-- Arbitration tribunal declared that PM647 is within Prime Medicine’s “Field”, confirming Prime Medicine’s right to develop and commercialize PM647 in AATD --  -- Prime Medicine owes no monetary dama","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3324031/0/en/Prime-Medicine-Announces-Positive-Resolution-to-Arbitration-with-Beam-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","BK4139","IND","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649999894","title":"Insider Traders Lose US$34k As Indaptus Therapeutics Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2649999894","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649999894?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:47","pubTimestamp":1783511263,"startTime":"0","endTime":"0","summary":"The recent price decline of 11% in Indaptus Therapeutics, Inc.'s ( NASDAQ:INDP ) stock may have disappointed insiders...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indp/indaptus-therapeutics/news/insider-traders-lose-us34k-as-indaptus-therapeutics-drops","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indp/indaptus-therapeutics/news/insider-traders-lose-us34k-as-indaptus-therapeutics-drops","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","BK4007","BK4539","BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649993503","title":"IMPACT Therapeutics Sets Date and Shareholder Rules for 2026 Extraordinary Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2649993503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649993503?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:37","pubTimestamp":1783510648,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. Class H ( ($HK:7630) ) just unveiled an announcement. IMPACT Therapeutics, Inc. has announced plans to convene its first ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/impact-therapeutics-sets-date-and-shareholder-rules-for-2026-extraordinary-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/impact-therapeutics-sets-date-and-shareholder-rules-for-2026-extraordinary-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649993698","title":"Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2649993698","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649993698?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:35","pubTimestamp":1783510500,"startTime":"0","endTime":"0","summary":"Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3323986/0/en/Chemomab-Therapeutics-and-Precision-Medicine-Pioneer-Scipher-Medicine-Announce-Merger-Agreement-to-Advance-Nebokitug-in-an-AI-Powered-Phase-2-Trial-in-Rheumatoid-Arthritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","LU2500361329.USD","BK4539","BK4208","LFSC","LU2346227817.USD","CHAT","BK4139","ARTY","BK4585","LU0553294199.USD","VTHR","AIPO","GDOC","AGIX","LU0949170772.SGD","MEDX","LU0661504455.SGD","BK4007","CMS","LU1894683348.USD","RA","LENZ","LU1003077747.HKD","QTOC","LU0545039389.USD","BMED","LU0738911758.USD","LU1894683264.USD","BK4588","LU2637428348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649998732","title":"Raymond James Upgrades Tvardi Therapeutics to Outperform From Market Perform","url":"https://stock-news.laohu8.com/highlight/detail?id=2649998732","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649998732?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:27","pubTimestamp":1783510071,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics (TVRD) has an average rating of overweight and mean price target of $8.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649263998","title":"Ovid Therapeutics CFO Jeffrey Rona to step down, Charles Carter to succeed","url":"https://stock-news.laohu8.com/highlight/detail?id=2649263998","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649263998?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:25","pubTimestamp":1783509910,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics (OVID) announced several strategic appointments. Kevin Norrett will join Ovid as chief business officer to spearhead business and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ovid-therapeutics-cfo-jeffrey-rona-to-step-down-charles-carter-to-succeed-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ovid-therapeutics-cfo-jeffrey-rona-to-step-down-charles-carter-to-succeed-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","BK4539","OVID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649967603","title":"Tvardi Therapeutics Raised to Outperform from Market Perform by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2649967603","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649967603?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:12","pubTimestamp":1783505520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVRD/analyst-ratings(END) Dow Jones NewswiresJuly 08, 2026 06:12 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RJF","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649962994","title":"Tvardi Therapeutics upgraded to Outperform from Market Perform at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2649962994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649962994?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:45","pubTimestamp":1783503922,"startTime":"0","endTime":"0","summary":"Raymond James analyst Ryan Deschner upgraded Tvardi Therapeutics (TVRD) to Outperform from Market Perform with a $10 price target after Phase 1 dat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-upgraded-to-outperform-from-market-perform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-upgraded-to-outperform-from-market-perform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649647109","title":"Addex Therapeutics announces publication of new ADX71743 preclinical research","url":"https://stock-news.laohu8.com/highlight/detail?id=2649647109","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649647109?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:15","pubTimestamp":1783502113,"startTime":"0","endTime":"0","summary":"Addex Therapeutics (ADXN) announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-announces-publication-of-new-adx71743-preclinical-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-announces-publication-of-new-adx71743-preclinical-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ADXN","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":0.0587},{"period":"1month","weight":-0.0878},{"period":"3month","weight":-0.3402},{"period":"6month","weight":-0.5878},{"period":"1year","weight":-0.8045},{"period":"ytd","weight":-0.6169}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0084},{"period":"3month","weight":0.0963},{"period":"6month","weight":0.074},{"period":"1year","weight":0.2016},{"period":"ytd","weight":0.0931}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.666667,"avgChangeRate":0.057438},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction